Constellation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is primarily if focused on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression and drug resistance. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-1205, and the other program is evaluating a compound, CPI-0610.
Q3 2019(9/30/19): Cash 89.07M. Loss 21.15M
EPS and Sales:
|Date||EPS||% last year||% last quarter|
Total institutions: 56，no change
Shares hold: 20670.8k shares. no change
shares% hold: 61.64%，no change